EMMX Biotechnology

EMMX Biotechnology is a clinical-stage biopharmaceutical company specializing in the discovery and development of innovative therapies targeting G-protein coupled receptors (GPCRs). Headquartered in Shenzhen, China, the company utilizes a proprietary platform that integrates structural biology, cryo-electron microscopy (Cryo-EM), and computational chemistry to overcome traditional challenges in GPCR drug discovery. Their pipeline primarily focuses on high-impact therapeutic areas including metabolic disorders, oncology, and inflammatory diseases. EMMX aims to leverage its deep expertise in GPCR pharmacology to deliver first-in-class or best-in-class treatments, particularly focusing on therapeutic antibodies for targets previously considered undruggable.